| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/22/2007 | US20070065516 Composition improved in the solubility or oral absorbability |
| 03/22/2007 | US20070065515 Methods and compositions for treating skin lines and wrinkles and improving skin quality |
| 03/22/2007 | US20070065514 tumor necrosis factor alpha (TNF alpha ) mutein attached to substrates, to create an adsorbent matrix, that permit binding of immune system inhibitors such as soluble TNF receptors, thereby inducing a vigorous immune response while minimizing toxicity |
| 03/22/2007 | US20070065513 Stable lansoprazole formulation |
| 03/22/2007 | US20070065512 Modified and immediate release formulations of memantine |
| 03/22/2007 | US20070065511 Controlled delivery creatine formulations and method of using the same |
| 03/22/2007 | US20070065510 Novel controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| 03/22/2007 | US20070065509 Comprises ciprofloxacin and hydroxypropylmethylcellulose for improving visocisty |
| 03/22/2007 | US20070065508 Composition Comprising Vitamin B12 and Acid Reducing Agent and Uses Thereof |
| 03/22/2007 | US20070065507 For treatment of osteoporosis is formulated with an amount of a polydimethylsiloxane antifoam agent, and an antacid, a vitamin D derivative, or a calcium supplement; for reducing foaming in the stomach, leading to reduced reflux and oesophageal irritation |
| 03/22/2007 | US20070065506 Keratin and soluble derivatives thereof for a nutraceutical and to reduce oxidative stress and to reduce inflammation and to promote skin health |
| 03/22/2007 | US20070065505 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form |
| 03/22/2007 | US20070065504 Inserting solid dosage form, comprising hard fats that melt body temperature surrounded by solid gelatin capsule, comprising antifungal (miconazole nitrate) or antibacterial agents (metronidazole) after patient awakens until thirty minutes prior to patient sleeps |
| 03/22/2007 | US20070065503 Active substance-doped absorbing polymer particles, composition comprising polycondensate matrix and absorbant polymer for release of a wound treatment substance |
| 03/22/2007 | US20070065502 Methods and apparatus for sealing capsules |
| 03/22/2007 | US20070065501 Method for banding hard capsules using hydroxypropylmethyl cellulose (HPMC) as a base |
| 03/22/2007 | US20070065500 Northern white kidney bean extract and red kidney bean extract in combination with green tea extract in the treatment of obesity |
| 03/22/2007 | US20070065499 Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
| 03/22/2007 | US20070065498 Encapsulated arsenic drugs |
| 03/22/2007 | US20070065497 Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy |
| 03/22/2007 | US20070065496 Dermal therapeutic system comprising 2-(3-benzophenyl)propionic acid |
| 03/22/2007 | US20070065495 Transdermal hormone delivery system: compositions and methods |
| 03/22/2007 | US20070065494 Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
| 03/22/2007 | US20070065493 External patch containing estrogen and/or progestogen |
| 03/22/2007 | US20070065492 Cladribine formulations for improved oral and transmucosal delivery |
| 03/22/2007 | US20070065491 Devices and methods for the delivery of blood clotting materials to bleeding wounds |
| 03/22/2007 | US20070065489 Hair holder |
| 03/22/2007 | US20070065483 In vivo formed matrices including natural biodegradable polysaccharides and uses thereof |
| 03/22/2007 | US20070065469 Liquid formulations with high concentration of human growth hormone (high) comprising glycine |
| 03/22/2007 | US20070065454 Liposomal vaccine |
| 03/22/2007 | US20070065437 Anti-CD3 antibody formulations |
| 03/22/2007 | US20070065432 Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| 03/22/2007 | US20070065374 Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| 03/22/2007 | US20070065373 Mucoactive agents for treating a pulmonary disease |
| 03/22/2007 | US20070065372 Process for the production of particles |
| 03/22/2007 | US20070065371 Novel Dry Powder Inhalation System For Transpulmonary Administration |
| 03/22/2007 | US20070065370 Suspension aerosol formulationis of pharmaceutical products |
| 03/22/2007 | US20070065369 Bioavailability; delivery to deep lung; lipid based microstructure; rapid release and absorption |
| 03/22/2007 | US20070065368 Compositions and Methods for Suppressing Fibrocytes and for Detecting Fibrocyte Differentiation |
| 03/22/2007 | US20070065367 Method of treating pulmonary disease with interferons |
| 03/22/2007 | US20070065366 Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation |
| 03/22/2007 | US20070065365 Abuse-resistant transdermal system |
| 03/22/2007 | US20070065364 Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same |
| 03/22/2007 | US20070062548 Inhaler for basic pharmaceutical agents and method for the production thereof |
| 03/22/2007 | DE10392945T5 Beschichtetes Mikromaschen-Dental-Produkt, das mit einem eingebetteten, aus Partikeln bestehenden Stoff überzogen ist Coated micromesh dental product, which is coated with an embedded, the particulate material |
| 03/22/2007 | DE102005044400A1 Verfahren zur Verkapselung und kontrollierten Freisetzung von schwer wasserlöslichen (hydrophoben) flüssigen und festen Wirkstoffen Process for encapsulation and controlled release of poorly water-soluble (hydrophobic) liquid and solid substances |
| 03/22/2007 | DE102004034355B4 Kapsel zum Freisetzen von in ihr befindlichen Wirksoffen an definierten Orten in einem Körper Capsule to release of in their active open at defined locations in a body |
| 03/22/2007 | CA2845251A1 Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof |
| 03/22/2007 | CA2818900A1 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| 03/22/2007 | CA2622624A1 Topical film-forming monophasic formulations |
| 03/22/2007 | CA2622468A1 Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof |
| 03/22/2007 | CA2622457A1 Ion exchange resin treated to control swelling |
| 03/22/2007 | CA2622368A1 Liposomes for treatment of multiple myeloma |
| 03/22/2007 | CA2622200A1 Nanoparticulate tadalafil formulations |
| 03/22/2007 | CA2622196A1 Process for the encapsulation and controlled release of sparingly water-soluble (hydrophobic) liquid and solid active ingredients |
| 03/22/2007 | CA2621806A1 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| 03/22/2007 | CA2621641A1 Ph sensitive nanoparticle formulation for oral delivery of proteins/peptides |
| 03/22/2007 | CA2621492A1 Surfactant systems for delivery of organic compounds |
| 03/22/2007 | CA2621399A1 Combinations comprising a vegf receptor inhibitor and a penetration enhancer |
| 03/22/2007 | CA2621273A1 Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| 03/22/2007 | CA2621270A1 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation |
| 03/22/2007 | CA2621266A1 Sustained-release formulation comprising a glucuronate salt of a piperazine compound and uses thereof |
| 03/22/2007 | CA2620758A1 Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| 03/22/2007 | CA2620370A1 Extended release pharmaceutical composition of metformin and a process for producing it |
| 03/22/2007 | CA2620299A1 Particulate lipid pharmaceutical composition |
| 03/22/2007 | CA2612769A1 Improved pharmaceutical composition containing hmg-coa reductase inhibitor and method for the preparation thereof |
| 03/21/2007 | EP1764181A1 Laser drilling system and method |
| 03/21/2007 | EP1764180A1 Laser drilling system and method |
| 03/21/2007 | EP1764111A1 Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility |
| 03/21/2007 | EP1764110A1 Compositions comprising an insulin sensitivity enhancer and a biguanide |
| 03/21/2007 | EP1764103A2 Crystalline amifostine compositions and methods for the preparation and use of same |
| 03/21/2007 | EP1764102A1 Quinolone-containing medicinal composition |
| 03/21/2007 | EP1764100A2 Compositions and methods for reducing vaginal pH |
| 03/21/2007 | EP1764091A2 Improvements in or relating to amphoteric liposomes |
| 03/21/2007 | EP1764090A1 Amphoteric liposomes for local drug applications |
| 03/21/2007 | EP1764089A1 Serum stable liposomes comprising amphoter II lipid mixtures |
| 03/21/2007 | EP1764088A1 Thixotropic personal lubricant containing carageenan |
| 03/21/2007 | EP1764078A1 Microcapsules with aqueous core and their use in cosmetic compositions |
| 03/21/2007 | EP1763576A2 Ex-vivo application of solid microparticulate therapeutic agents |
| 03/21/2007 | EP1763397A1 System for manufacturing micro-spheres |
| 03/21/2007 | EP1763374A2 In situ hardening paste, its manufacturing and use |
| 03/21/2007 | EP1763340A2 Rapidly dispersible, fine-grained, separation-resistant pulverulent film coating agent, based on polyvinyl alcohol-polyether graft copolymers and characterised by a particular physical stability and a low degree of roughness |
| 03/21/2007 | EP1763339A1 Oral antimicrobial pharmceutical compositions |
| 03/21/2007 | EP1763338A2 Oral sustained release formulation of tedisamil with gastric retention properties |
| 03/21/2007 | EP1763337A2 Immediate, controlled and sustained release formulations of galanthamine |
| 03/21/2007 | EP1763336A1 Hydrophobic ophthalmic compositions and methods of use |
| 03/21/2007 | EP1763300A1 Use of ether group-containing polymers as solubilizers |
| 03/21/2007 | EP1663141B1 Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline |
| 03/21/2007 | EP1651270B1 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 03/21/2007 | EP1498142B1 Polyfunctional biocompatible hydrogel and method for the production thereof |
| 03/21/2007 | EP1496864B1 Pharmaceutical composition containing lamotrigine particles of defined morphology |
| 03/21/2007 | EP1467711B1 Dna dosage forms |
| 03/21/2007 | EP1465607B1 Pharmaceutical formulations with modified release |
| 03/21/2007 | EP1455782B1 High-concentration stable meloxicam solutions for needle-less injection |
| 03/21/2007 | EP1397127B1 Solid pharmaceutucal formulations comprising modafinil |
| 03/21/2007 | EP1385492B1 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 03/21/2007 | EP1361867B1 Fibrate-statin combinations with reduced fed-fasted effects |
| 03/21/2007 | EP1296663B1 Highly efficient delivery of a large therapeutic mass aerosol |
| 03/21/2007 | EP1289529B1 Active substance combination containing a compound with an opioid effect and at least one further compound of formula i |
| 03/21/2007 | EP1263460B1 Pharmaceutical carrier composition for papayne based products |